Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500 UK 2026: Complete Research Reference | Peptides Lab UK

TB-500 UK 2026: Complete Research Reference | Peptides Lab UK Important regulatory notice. TB-500 is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound a

By Recovery & Performance Peptides Editorial Team

TB-500 UK 2026: Complete Research Reference | Peptides Lab UK

Important regulatory notice. TB-500 is not licensed by the MHRA for human or veterinary use in the United Kingdom. It is supplied to the laboratory market as a research-use-only reference compound and appears on the WADA Prohibited List in sport. This page is a literature-context overview and trust-signal sourcing reference. It is not personal-use guidance and Peptides Lab UK does not endorse any human or veterinary use of TB-500.

Quick reference summary. TB-500 is a synthetic peptide containing an active fragment from thymosin beta-4 (TB4), a naturally occurring protein implicated in cellular migration, actin biology and angiogenesis in the published cell-biology literature. The published TB-500 research is dominated by in-vitro and small-animal model work. TB-500 is on the WADA Prohibited List and is not licensed in any major jurisdiction. Peptides Lab UK supplies TB-500 as a research-use-only laboratory reference compound with batch-specific HPLC certificates of analysis.

UK regulatory and sport-testing position (2026)

TB-500 has no UK marketing authorisation. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. TB-500 is also banned in WADA-accredited anti-doping testing under the peptide hormones, growth factors, related substances and mimetics class. WADA-accredited laboratories run targeted assays for TB-500. Anyone competing under WADA, UK Anti-Doping (UKAD), professional federation rules or military testing should treat TB-500 as a detectable banned substance.

What the molecule actually is

TB-500 is a synthetic peptide that contains an active sequence from thymosin beta-4. Thymosin beta-4 is a naturally occurring 43-amino-acid protein found in most mammalian cells. The published cell-biology literature describes TB4 in the context of cellular migration, actin polymerisation regulation, and angiogenesis-related gene expression.

What the published research record covers

The peer-reviewed TB-500 and TB4 literature is dominated by in-vitro cell-culture studies of cellular migration, actin biology and signal transduction, plus rodent-model studies of soft-tissue repair (tendon, ligament) and cardiac models of myocardial injury. Large blinded placebo-controlled human clinical trials of TB-500 are not available, and TB-500 has not been advanced through the regulated drug-development pathway by any pharmaceutical sponsor.

Quality requirements for a research-grade reference sample

For laboratory researchers, identity and purity are the only metrics that matter. A responsible supplier publishes:

Batch-specific certificate of analysis (COA), downloadable per batch

Third-party HPLC purity data with chromatogram

Mass-spectrometry identity confirmation against the TB-500 reference standard

Clear research-use-only labelling, with no human or veterinary use claim

Stability and storage data for the supplied batch

Peptides Lab UK supplies TB-500 on this basis. View our research-grade TB-500 listing for batch documentation, packaging and pricing.

How to evaluate any UK TB-500 supplier

Five questions to ask any UK supplier before placing a research-grade order. (1) Does each batch ship with a third-party HPLC COA? (2) Is mass-spectrometry identity confirmation available? (3) Is the labelling research-use-only with no human-use claims? (4) Is the supplier transparent about source manufacturing and storage chain? (5) Does the supplier publish stability data for the supplied batch? Any ‘no’ or vague answer is a red flag in the current UK enforcement environment.

For laboratory researchers

If you are working in cell migration biology, actin chemistry, angiogenesis, or small-animal soft-tissue or cardiac repair models, TB-500 is a research reference compound with a substantial cell-biology and rodent-model publication trail. The primary literature is indexed on PubMed. For a research-grade reference sample with batch-specific HPLC and COA documentation, see the TB-500 product listing.

Frequently Asked Questions

Is TB-500 licensed in the UK?

No. TB-500 has not received MHRA, EMA or FDA marketing authorisation.

Is TB-500 banned in sport?

Yes. TB-500 is on the WADA Prohibited List and WADA-accredited laboratories run targeted assays for it.

What does the published research record cover?

In-vitro cell-biology of actin and migration, plus rodent-model soft-tissue and cardiac repair studies. Published large human clinical-trial data is not available.

What should a research-grade TB-500 reference sample come with?

Batch-specific COA, third-party HPLC purity data, mass-spectrometry identity confirmation, clear research-use-only labelling, and stability documentation.

Where can I read the source literature?

The peer-reviewed thymosin beta-4 and TB-500 literature is indexed on PubMed.

Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use. TB-500 is also banned in sport under the WADA Prohibited List.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

TB-500 Dosing Protocols and Administration Methods

Research protocols for TB-500 in tendon repair typically use subcutaneous injection at doses ranging from 2–5mg administered twice weekly for 4–6 weeks, followed by a maintenance phase at reduced frequency. Equine studies (which provide the most extensive TB-500 tendon repair data) used 10–20mg weekly for large animals. Human equivalent doses scale to approximately 2–3mg twice weekly based on body weight conversion. Subcutaneous administration allows systemic distribution. TB-500 doesn't need to be injected directly into the injury site. The peptide circulates and accumulates in areas of active tissue repair due to upregulated receptor expression in damaged zones. Some protocols include a loading phase with higher frequency (daily administration for the first 7–10 days) to rapidly elevate circulating thymosin beta-4 levels, followed by twice-weekly maintenance dosing. Reconstitution requires bacteriostatic water. Lyophilized TB-500 is reconstituted at 2mg/mL and stored at 2–8°C for up to 28 days. Once reconstituted, the peptide is sensitive to temperature degradation; any storage above 8°C for extended periods compromises potency. Real Peptides prepares TB-500 through small-batch synthesis with verified amino acid sequencing to ensure the active peptide structure remains intact through storage and reconstitution. Cycle length in research settings typically runs 6–8 weeks for acute injuries and 8–12 weeks for chronic tendinopathy cases where significant collagen disorganizati…
02

Question drills

Open a question for its connected answer.

01What If TB-500 Is Administered After Acute Tissue Injury — Does Timing Matter?+

Administer TB-500 within the first 24–48 hours post-injury for maximal effect on the tb-500 signaling pathway. The acute inflammatory phase creates a chemotactic gradient that directs cell migration, and TB-500's actin-sequestering and integrin-upregulating effects amplify the cellular response to those gradients. Delayed administration (beyond 72 hours) still provides benefit but with reduced magnitude. Cells have already begun migrating without the enhanced cytoskeletal machinery TB-500 provides. Animal models of myocardial infarction show that TB-500 given within 6 hours post-occlusion reduces infarct size by 30% versus 15% when given at 72 hours.

SOURCE / realpeptides.co ↗
02What If TB-500 Is Administered After Actin Filaments Have Already Polymerized at the Injury Site?+

Therapeutic efficacy drops significantly. TB-500 works by sequestering monomeric actin before polymerization. Once filaments are established (typically 48–72 hours post-injury), the peptide cannot reverse existing structures. Peak efficacy occurs when TB-500 is administered within 24 hours of tissue damage, when cellular migration is most active and actin turnover rates are highest. Delayed administration may still provide modest angiogenic benefit through VEGF upregulation, but the migration-enhancing effect is largely lost.

SOURCE / realpeptides.co ↗
03What If the Reconstituted Solution Looks Cloudy or Has Particles Floating in It?+

Discard the vial immediately. Cloudiness indicates protein aggregation or bacterial contamination. Both render the peptide unusable. Aggregated peptides lose biological activity because the folded structure required for receptor binding is disrupted. Particulate matter suggests either contamination during reconstitution or breakdown of the lyophilized cake before mixing. Do not filter the solution or attempt to use it. The risk of injecting inactive or contaminated compound outweighs the cost of the vial.

SOURCE / realpeptides.co ↗
04What If Your Experimental Timeline Requires Faster Results?+

Shorten measurement intervals to 6 and 12 hours rather than 24 hours. TB-500's cytoskeletal effects begin within 30 minutes, and migration rate differences often become statistically significant by 6 hours in scratch assays. Use time-lapse microscopy with automated tracking software (Incucyte, ImageJ with MTrackJ plugin) to capture continuous data rather than endpoint measurements. Pretreat cells with TB-500 for 4 hours before initiating migration to maximize early-phase velocity differences.

SOURCE / realpeptides.co ↗
05What If the Injury Model Includes Concurrent Infection or Contamination?+

Control infection independently before assessing TB-500's repair effects, or use a separate antimicrobial intervention. TB-500 has no direct antimicrobial activity. It modulates cytoskeletal dynamics, not pathogen clearance. Animal studies using contaminated wound models show that TB-500 improves epithelial migration and collagen remodeling only after bacterial load is reduced below 10^5 CFU/gram tissue. Infected wounds remain in a prolonged inflammatory state where neutrophil infiltration and proteolytic enzyme activity prevent the transition to the proliferative phase where TB-500 acts. One dermal wound study in rats co-administered topical mupirocin with TB-500 and achieved normal re-epithelialization rates; TB-500 alone in contaminated wounds showed no benefit until infection resolved.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Ethical Considerations and Responsible Research

As with any powerful biological agent, the ethical considerations surrounding TB-500 for cardiac repair research are paramount. We advocate for stringent adherence to scientific protocols, ethical guidelines, and responsible research practices. The scientific community has a collective duty to ensure that these groundbreaking discoveries are pursued with integrity and a focus on patient safety, ultimately benefiting humanity. At Real Peptides, we understand the gravity of this responsibility. We're not just suppliers; we're partners in discovery. Our commitment to providing research-grade peptides means we prioritize purity, consistency, and transparent data. When you're working with compounds like TB-500 (thymosin Beta-4), you need to know exactly what you're getting. That's our promise. We encourage researchers to engage in open dialogue, collaborate widely, and share findings to accelerate progress while maintaining the highest ethical standards. This collective effort is what drives true innovation in fields like TB-500 for cardiac repair. It's a shared journey, really.

RESEARCH

The Role of Precision and Purity in Advancing TB-500 Research

Our collective expertise at Real Peptides underscores a fundamental truth in biological research: the quality of your reagents directly dictates the validity of your results. This is particularly salient for complex peptides like TB-500 (thymosin Beta-4), where subtle impurities can drastically alter cellular responses. We're not just suppliers; we’re partners in scientific discovery, ensuring every batch meets rigorous standards. Imagine conducting months of intricate experiments on TB-500 cardiac repair, only to find inconsistent data due to substandard peptide synthesis. It’s a researcher’s nightmare, frankly. That's why our commitment to small-batch synthesis and exact amino-acid sequencing isn’t merely a marketing claim; it’s a foundational principle. It’s how we ensure that when you explore the profound potential of TB-500 (thymosin Beta-4), you’re working with a compound that truly reflects its intended biological activity. In 2026, with the rapid pace of scientific advancement, having a reliable source for high-purity peptides is more crucial than ever. Our stringent quality control measures ensure that every peptide we provide, from Adamax Peptide 10mg to Tesamorelin 10mg and everything in between, is precisely what your research demands. This dedication is what truly sets us apart in a crowded marketplace. You can Explore High-Purity Research Peptides directly on our platform.

POTENTIAL BENEFITS

What Are the Benefits of TB-500?

By supporting cellular repair and regeneration pathways, TB-500 may offer several wellness-focused benefits, including:
05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles